AcelRx Pharmaceuticals, Inc. is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain. Its lead product candidates include ARX-04, Zalviso, which utilize sublingual sufentanil, delivered through a non-invasive route of administration, and ARX-03. ARX-04 is meant for the treatment of moderate-to-severe acute pain to be administered by a healthcare professional to a patient in medically supervised settings. Zalviso is meant for the management of moderate-to-severe acute pain in hospitalized adult patients. ARX-03 provides mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician's office. It also includes ARX-02, which is meant for the treatment of patients who suffer from breakthrough pain (BTP) due to cancer.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:ACRX
- CUSIP: N/A
- Web: www.acelrx.com
Capitalization:- Market Cap: $164.49 million
- Outstanding Shares: 45,380,000
Average Prices:- 50 Day Moving Avg: $2.38
- 200 Day Moving Avg: $2.71
- 52 Week Range: $1.95 - $4.08
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -4.21
- P/E Growth: 0.000
Sales & Book Value:- Annual Revenue: $17.44 million
- Price / Sales: 9.43
- Book Value: ($0.43) per share
- Price / Book: -8.37
Profitability:- EBIDTA: ($33,490,000.00)
- Net Margins: -273.65%
- Return on Equity: -478.66%
- Return on Assets: -46.79%
Debt:- Debt-to-Equity Ratio: -0.84%
- Current Ratio: 6.12%
- Quick Ratio: 5.97%
Misc:- Average Volume: 691,721 shs.
- Beta: 2.78
- Short Ratio: 5.66
Frequently Asked Questions for AcelRx Pharmaceuticals (NASDAQ:ACRX)
What is AcelRx Pharmaceuticals' stock symbol?
AcelRx Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACRX."
How were AcelRx Pharmaceuticals' earnings last quarter?
AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) issued its quarterly earnings data on Monday, May, 8th. The company reported ($0.34) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.28) by $0.06. The business earned $3.11 million during the quarter, compared to the consensus estimate of $2.36 million. AcelRx Pharmaceuticals had a negative return on equity of 478.66% and a negative net margin of 273.65%. View AcelRx Pharmaceuticals' Earnings History.
When will AcelRx Pharmaceuticals make its next earnings announcement?
Where is AcelRx Pharmaceuticals' stock going? Where will AcelRx Pharmaceuticals' stock price be in 2017?
6 brokers have issued 1-year target prices for AcelRx Pharmaceuticals' stock. Their predictions range from $6.00 to $15.00. On average, they expect AcelRx Pharmaceuticals' share price to reach $9.80 in the next twelve months. View Analyst Ratings for AcelRx Pharmaceuticals.
What are analysts saying about AcelRx Pharmaceuticals stock?
Here are some recent quotes from research analysts about AcelRx Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of pain. The Company product candidates comprises: ARX-01 or the Sufentanil NanoTab PCA System; ARX-02 or the Sufentanil NanoTab BTP Management System; and ARX-03 or the Sufentanil/Triazolam NanoTab which are in their development stage. Its product ARX-01 is focused on acute post-operative pain, ARX-02 is focused on the treatment of cancer breakthrough pain and ARX-03 is focused on providing mild sedation, anxiety reduction, and pain relief to patients undergoing painful procedures in a physician's office. AcelRx Pharmaceuticals, Inc. is headquartered in Redwood City, California. " (7/11/2017)
- 2. Stifel Nicolaus analysts commented, "Arc Logistics Partners LP reported 4Q16 Adjusted EBITDA of $13.9 million, below our estimate of $14.9 million, and distributable cash flow (DCF) of $11.0 million against our estimate of $11.1 million. Adjusted EBITDA came in below our estimates due to slightly lower revenues and higher operating expense on the quarter. Management provided an update on the ongoing Gulf LNG arbitration case and noted that the arbitration panel has heard the arguments and is in the process of rendering a decision. With that said, a timeline for a decision was not provided. On the call management highlighted their belief that the Gulf arbitration is acting as an overhang on ARCX units and expect a resolution to provide uplift to the partnership's valuation (assuming a positive outcome). Although we ultimately expect a favorable resolution for ARCX in the Gulf LNG arbitration, a full valuation and uncertainty over the outcome are keeping us on the sidelines. At this time we are maintaining our Hold rating." (3/14/2017)
- 3. Royal Bank Of Canada analysts commented, "ACRX reported 4Q results after the close where focus was primarily on the upcoming DSUVIA (ARX-04) launch, the expected AdCom meeting prior to approval, and progress with the Zalviso trial and the EU launch. We continue to view the story as on-track and make only minor adjustments to our model. We reiterate our Outperform rating and $6 PT." (3/3/2017)
Who are some of AcelRx Pharmaceuticals' key competitors?
Some companies that are related to AcelRx Pharmaceuticals include Corbus Pharmaceuticals Holdings (CRBP), Rigel Pharmaceuticals (RIGL), Edge Therapeutics (EDGE), Merus N.V. (MRUS), Minerva Neurosciences (NERV), AVEO Pharmaceuticals (AVEO), DURECT Corporation (DRRX), Ardelyx (ARDX), Immune Design Corp. (IMDZ), Circassia Pharmaceuticals PLC (CIR), Oxford BioMedica plc (OXB), Clearside Biomedical (CLSD), Catalyst Pharmaceuticals (CPRX), ObsEva SA (OBSV), Pieris Pharmaceuticals (PIRS), Stemline Therapeutics (STML), Chimerix (CMRX) and Cempra (CEMP).
Who are AcelRx Pharmaceuticals' key executives?
AcelRx Pharmaceuticals' management team includes the folowing people:
- Adrian Adams, Independent Chairman of the Board
- Richard A. King, President
- Vincent J. Angotti, Chief Executive Officer, Interim Chief Financial Officer
- Pamela P. Palmer M.D. Ph.D., Chief Medical Officer, Director
- Badri N. Dasu, Chief Engineering Officer
- Lawrence G. Hamel, Chief Development Officer
- Jane Wright-Mitchell, Chief Legal Officer
- Richard F. Afable M.D., Director
- Howard B. Rosen, Director
- Mark G. Edwards, Independent Director
How do I buy AcelRx Pharmaceuticals stock?
Shares of AcelRx Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AcelRx Pharmaceuticals' stock price today?
One share of AcelRx Pharmaceuticals stock can currently be purchased for approximately $3.62.
MarketBeat Community Rating for AcelRx Pharmaceuticals (NASDAQ ACRX)MarketBeat's community ratings are surveys of what our community members think about AcelRx Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for AcelRx Pharmaceuticals (NASDAQ:ACRX) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 2 Hold Ratings, 4 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.67) |
| Consensus Price Target: | $9.80 (170.36% upside) |
Analysts' Ratings History for AcelRx Pharmaceuticals (NASDAQ:ACRX)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 7/14/2017 | Jefferies Group LLC | Reiterated Rating | Buy -> Buy | $7.00 | High |  |
| 3/14/2017 | Stifel Nicolaus | Lower Price Target | Hold | $15.00 -> $14.00 | Low | |
| 3/6/2017 | Cowen and Company | Reiterated Rating | Hold | | N/A | |
| 3/6/2017 | Roth Capital | Set Price Target | Buy | $15.00 | N/A | |
| 3/3/2017 | Royal Bank Of Canada | Reiterated Rating | Outperform | $6.00 | N/A | |
| 12/5/2016 | HC Wainwright | Reiterated Rating | Buy | $7.00 | N/A | |
| 5/6/2016 | Seaport Global Securities | Upgrade | Accumulate -> Buy | | N/A | |
| 4/14/2016 | Janney Montgomery Scott | Initiated Coverage | Neutral | | N/A | |
(Data available from 7/24/2015 forward)
Earnings History for AcelRx Pharmaceuticals (NASDAQ:ACRX)Earnings History by Quarter for AcelRx Pharmaceuticals (NASDAQ ACRX)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 7/26/2017 | | ($0.27) | | | | | N/A | |
| 5/8/2017 | Q1 2017 | ($0.28) | ($0.34) | $2.36 million | $3.11 million | View | Listen | |
| 3/2/2017 | Q4 2016 | ($0.23) | ($0.21) | $3.05 million | $6.44 million | View | Listen | |
| 11/1/2016 | Q316 | ($0.23) | ($0.25) | $2.89 million | $1.60 million | View | N/A | |
| 7/28/2016 | Q216 | ($0.22) | ($0.24) | $2.17 million | $4.53 million | View | Listen | |
| 3/7/2016 | Q415 | ($0.10) | ($0.24) | $4.97 million | $1.73 million | View | Listen | |
| 10/29/2015 | Q315 | ($0.23) | $0.11 | $1.75 million | $13.90 million | View | Listen | |
| 8/3/2015 | Q215 | ($0.26) | ($0.20) | $0.30 million | $1.92 million | View | Listen | |
| 5/4/2015 | Q115 | ($0.28) | ($0.27) | $0.40 million | $0.18 million | View | N/A | |
| 11/10/2014 | Q4 2014 | ($0.33) | ($0.32) | $4.95 million | $4.83 million | View | N/A | |
| 8/11/2014 | Q214 | ($0.27) | ($0.34) | $0.20 million | $0.07 million | View | N/A | |
| 5/8/2014 | Q114 | ($0.23) | ($0.22) | $0.28 million | $0.10 million | View | N/A | |
| 3/3/2014 | Q413 | ($0.17) | ($0.18) | $4.93 million | $27.60 million | View | N/A | |
| 11/5/2013 | Q313 | ($0.19) | ($0.26) | | | View | N/A | |
| 8/12/2013 | Q2 2013 | ($0.22) | ($0.22) | $1.73 million | $0.41 million | View | Listen | |
| 11/6/2012 | Q312 | ($0.38) | ($0.38) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for AcelRx Pharmaceuticals (NASDAQ:ACRX)2017 EPS Consensus Estimate: ($0.89)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.21) | ($0.21) | ($0.21) |
| Q2 2017 | 1 | ($0.22) | ($0.22) | ($0.22) |
| Q3 2017 | 1 | ($0.23) | ($0.23) | ($0.23) |
| Q4 2017 | 2 | ($0.26) | ($0.19) | ($0.23) |
(Data provided by Zacks Investment Research)
Dividend History for AcelRx Pharmaceuticals (NASDAQ:ACRX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for AcelRx Pharmaceuticals (NASDAQ:ACRX)Insider Ownership Percentage: 28.10%
Institutional Ownership Percentage: 30.32%
Insider Trades by Quarter for AcelRx Pharmaceuticals (NASDAQ:ACRX)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 6/19/2017 | Life Sciences Maste Perceptive | Major Shareholder | Sell | 875,000 | $2.40 | $2,100,000.00 | |
| 9/29/2016 | Perceptive Advisors Llc | Major Shareholder | Sell | 216,500 | $3.92 | $848,680.00 | |
| 9/15/2016 | Perceptive Advisors Llc | Major Shareholder | Sell | 392,850 | $3.70 | $1,453,545.00 | |
| 5/13/2016 | Howard B Rosen | CEO | Buy | 10,206 | $3.26 | $33,271.56 | |
| 5/12/2016 | Mark G Edwards | Director | Buy | 15,000 | $3.15 | $47,250.00 | |
| 11/18/2015 | Perceptive Advisors Llc | Major Shareholder | Sell | 176,200 | $5.35 | $942,670.00 | |
| 11/6/2015 | Perceptive Advisors Llc | Major Shareholder | Sell | 92,100 | $4.59 | $422,739.00 | |
| 9/9/2015 | Perceptive Advisors Llc | Major Shareholder | Sell | 310,000 | $4.18 | $1,295,800.00 | |
| 5/7/2015 | Mark G Edwards | Director | Buy | 40,000 | $3.13 | $125,200.00 | |
| 3/10/2014 | Mark Wan | Director | Sell | 1,000,000 | $12.35 | $12,350,000.00 | |
| 11/7/2013 | Perceptive Advisors Llc | major shareholder | Buy | 200,000 | $6.51 | $1,302,000.00 | |
| 11/4/2013 | Perceptive Advisors Llc | major shareholder | Buy | 155,000 | $6.87 | $1,064,850.00 | |
| 11/1/2013 | Perceptive Advisors Llc | Major Shareholder | Buy | 360,660 | $6.91 | $2,492,160.60 | |
| 9/20/2013 | Guy Nohra | Director | Sell | 158,153 | $10.59 | $1,674,840.27 | |
| 9/18/2013 | Guy Nohra | Director | Sell | 128,780 | $10.42 | $1,341,887.60 | |
| 7/23/2013 | Perceptive Advisors Llc | Major Shareholder | Buy | 850,000 | $11.65 | $9,902,500.00 | |
| 6/6/2013 | Mark G Edwards | Director | Buy | 10,000 | $8.10 | $81,000.00 | |
| 5/28/2013 | Adrian Adams | Director | Buy | 75,000 | $8.19 | $614,250.00 | |
| 12/7/2012 | Mark A Wan | Director | Buy | 2,416,918 | $3.31 | $7,999,998.58 | |
(Data available from 1/1/2013 forward)
Headline Trends for AcelRx Pharmaceuticals (NASDAQ:ACRX)
Latest Headlines for AcelRx Pharmaceuticals (NASDAQ:ACRX)
| Source: |
|
| Date | Headline |
|---|
 | -$0.28 EPS Expected for AcelRx Pharmaceuticals, Inc. (ACRX) This Quarter
www.americanbankingnews.com - July 24 at 12:40 PM |
 | Mid-Morning Market Update: Markets Mostly Flat; Philip Morris Profit Misses Estimates - Nasdaq
www.nasdaq.com - July 20 at 3:46 PM |
 | AcelRx Pharmaceuticals Appoints Raffi Asadorian as Chief Financial Officer
www.bizjournals.com - July 20 at 3:46 PM |
 | AcelRx Pharmaceuticals Appoints Raffi Asadorian as Chief Financial Officer - PR Newswire (press release)
www.prnewswire.com - July 19 at 3:46 PM |
| AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - July 19 at 9:00 AM |
| Biotech Stocks Growing Faster Than Other Sectors Fueled by Breakthroughs in R&D and Clinical Trials
www.prnewswire.com - July 18 at 3:46 PM |
 | Today's Research Reports on Stocks to Watch: AcelRx Pharmaceuticals and Sangamo Therapeutics
finance.yahoo.com - July 17 at 3:49 PM |
 | AcelRx: Undervalued Heading Into A Phase 3 Catalyst - Seeking Alpha
seekingalpha.com - July 16 at 3:12 PM |
| AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Given "Buy" Rating at Jefferies Group LLC
www.americanbankingnews.com - July 15 at 10:53 PM |
| Jefferies Sees Strong Upside in AcelRx Pharmaceuticals’ Shares and Set a $7 Price Target
finance.yahoo.com - July 14 at 5:14 PM |
| ETFs with exposure to AcelRx Pharmaceuticals, Inc. : July 12, 2017
finance.yahoo.com - July 12 at 3:47 PM |
| AcelRx Pharmaceuticals, Inc. (ACRX) Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - July 11 at 6:02 PM |
| AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - July 10 at 10:51 PM |
| ETFs with exposure to AcelRx Pharmaceuticals, Inc. : June 30, 2017
finance.yahoo.com - June 30 at 3:33 PM |
| Analysts Expect AcelRx Pharmaceuticals, Inc. (ACRX) Will Post Quarterly Sales of $2.63 Million
www.americanbankingnews.com - June 30 at 2:31 PM |
| AcelRx Pharmaceuticals, Inc. (ACRX) Expected to Post Earnings of -$0.28 Per Share
www.americanbankingnews.com - June 28 at 8:30 AM |
| AcelRx Pharmaceuticals, Inc. (ACRX) Major Shareholder Sells $2,100,000.00 in Stock
www.americanbankingnews.com - June 21 at 7:24 PM |
| AcelRx Pharmaceuticals, Inc. (ACRX) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - June 13 at 8:34 PM |
| ETFs with exposure to AcelRx Pharmaceuticals, Inc. : June 13, 2017
finance.yahoo.com - June 13 at 3:18 PM |
| AcelRx Pharmaceuticals (ACRX) Presents At Jefferies 2017 Global Healthcare Conference - Slideshow
seekingalpha.com - June 8 at 1:24 AM |
| $2.63 Million in Sales Expected for AcelRx Pharmaceuticals Inc (ACRX) This Quarter
www.americanbankingnews.com - June 4 at 9:52 AM |
| -$0.28 Earnings Per Share Expected for AcelRx Pharmaceuticals Inc (ACRX) This Quarter
www.americanbankingnews.com - June 2 at 7:34 AM |
| AcelRx Pharmaceuticals' ZALVISO Recognized for Innovative ... - PR Newswire (press release)
www.prnewswire.com - June 1 at 3:26 PM |
| AcelRx Pharmaceuticals' ZALVISO Recognized for Innovative Design with Prestigious Red Dot Award
finance.yahoo.com - June 1 at 3:26 PM |
| AcelRx Pharmaceuticals To Benefit From DSUVIA Launch - Seeking Alpha
seekingalpha.com - May 31 at 11:15 AM |
| AcelRx Pharmaceuticals to Present at Jefferies 2017 Global Healthcare Conference
finance.yahoo.com - May 31 at 11:15 AM |
| ETFs with exposure to AcelRx Pharmaceuticals, Inc. : May 22, 2017
finance.yahoo.com - May 22 at 3:19 PM |
| AcelRx Pharmaceuticals Inc (ACRX) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - May 19 at 8:56 PM |
| ETFs with exposure to AcelRx Pharmaceuticals, Inc. : May 11, 2017
finance.yahoo.com - May 11 at 8:31 PM |
| AcelRx Pharmaceuticals Inc (ACRX) Lowered to "Hold" at Zacks Investment Research
www.americanbankingnews.com - May 11 at 4:21 PM |
| AcelRx Pharmaceuticals, Inc. :ACRX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 10, 2017
finance.yahoo.com - May 10 at 3:26 PM |
| $2.45 Million in Sales Expected for AcelRx Pharmaceuticals Inc (ACRX) This Quarter
www.americanbankingnews.com - May 10 at 9:38 AM |
| AcelRx Pharmaceuticals Inc (ACRX) Posts Earnings Results, Misses Estimates By $0.06 EPS
www.americanbankingnews.com - May 9 at 10:22 AM |
| AcelRx Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - May 8 at 8:19 PM |
| AcelRx Pharmaceuticals reports 1Q loss
finance.yahoo.com - May 8 at 8:19 PM |
| Investor Network: AcelRx Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - May 8 at 11:27 AM |
| AcelRx Pharmaceuticals Inc (ACRX) Upgraded to Buy at Zacks Investment Research
www.americanbankingnews.com - May 3 at 6:36 PM |
| AcelRx Pharmaceuticals (ACRX) Given Media Impact Rating of 0.33
www.americanbankingnews.com - May 3 at 8:30 AM |
| AcelRx Pharmaceuticals (ACRX) Getting Somewhat Positive Press Coverage, Analysis Shows
www.americanbankingnews.com - April 30 at 11:17 AM |
| AcelRx Pharmaceuticals Inc (ACRX) Set to Announce Quarterly Earnings on Monday
www.americanbankingnews.com - April 29 at 1:21 AM |
| AcelRx Pharmaceuticals Inc (ACRX) Set to Announce Earnings on Monday
www.americanbankingnews.com - April 29 at 1:08 AM |
| AcelRx Pharmaceuticals to Hold First Quarter 2017 Financial Results Conference Call and Webcast on Monday, May ... - PR Newswire (press release)
www.prnewswire.com - April 28 at 8:40 PM |
| Somewhat Favorable Press Coverage Likely to Affect AcelRx Pharmaceuticals (ACRX) Stock Price
www.americanbankingnews.com - April 27 at 2:04 PM |
| AcelRx Pharmaceuticals to Hold First Quarter 2017 Financial Results Conference Call and Webcast on Monday, May ... - Yahoo Finance
finance.yahoo.com - April 26 at 3:27 PM |
| AcelRx Pharmaceuticals to Hold First Quarter 2017 Financial Results Conference Call and Webcast on Monday, May 8th, 2017
finance.yahoo.com - April 26 at 3:27 PM |
| AcelRx Pharmaceuticals (ACRX) Earning Somewhat Negative Media Coverage, Analysis Shows
www.americanbankingnews.com - April 24 at 11:47 AM |
| Somewhat Critical Media Coverage Very Likely to Impact AcelRx Pharmaceuticals (ACRX) Share Price
www.americanbankingnews.com - April 21 at 8:17 AM |
| AcelRx Pharmaceuticals Inc (ACRX) Expected to Announce Quarterly Sales of $1.85 Million
www.americanbankingnews.com - April 20 at 3:36 PM |
| -$0.28 EPS Expected for AcelRx Pharmaceuticals Inc (ACRX) This Quarter
www.americanbankingnews.com - April 18 at 11:23 AM |
| AcelRx Pharmaceuticals Reports Publication of Manuscripts Analyzing IV, Transdermal and Sublingual Patient ... - PR Newswire (press release)
www.prnewswire.com - April 15 at 3:18 PM |
AcelRx Pharmaceuticals (ACRX) Chart for Monday, July, 24, 2017
